Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, today announced plans for the transition of
Chief Financial Officer René Just and the appointment of Miguel
Coego Rios as Executive Vice President of Finance & Legal and
Interim CFO. René Just has resigned from the Company effective
March 31, 2022, after the expected filing date of CENTOGENE’s
Annual Report on Form 20-F. Miguel Coego Rios will join the Company
on February 08, 2022, and work closely through the transition with
current Chief Financial Officer René Just. The Company has
initiated a search for a permanent Chief Financial Officer; both
internal and external candidates will be evaluated.
"It is a privilege to welcome Miguel Coego Rios to the CENTOGENE
team. With more than a decade of experience in senior finance roles
in the biopharma sector, the expertise that Miguel brings is
invaluable. I have worked with him in previous roles, and we are
looking forward to the contributions he will bring to CENTOGENE as
we position ourselves as the unique and essential partner in rare,
metabolic and neurodegenerative diseases,” said Kim Stratton,
CENTOGENE’s Chief Executive Officer.
“The work that CENTOGENE is doing from diagnostics, to
discovery, to clinical development, to market access &
expansion, in rare, metabolic, and neurodegenerative diseases
offers real hope to patients around the world,” said Miguel Coego
Rios. “The Company has recently attracted a very solid financial
foundation to accelerate growth and innovation. CENTOGENE can now
focus on the next step in the evolution of its strategy, and I look
forward to enhancing the value of CENTOGENE by ensuring optimal
resource allocation on our strategic path forward and to thereby
contribute to maximizing stakeholder value. I am excited to be
joining a highly motivated team with the goal to deliver results
and inflection milestones.”
Miguel Coego Rios is an experienced senior executive with broad
expertise in finance and commercial leadership roles in the
pharmaceutical and biotech sectors. He has an extensive track
record in achieving sales and expenses targets, team management and
development, and steering multi-country projects. Most recently, he
was Vice President & General Manager South Europe at Orphazyme
A/S, a late-stage clinical biotech. Before that he was Vice
President & CFO EMEA at Mundipharma, a multinational
pharmaceutical company. Earlier in his career, he served in several
senior management positions at Shire Pharmaceuticals between 2011
and 2019, most recently as CFO LATAM and General Manager of the
Andean region. Miguel Coego Rios has gained notable international
exposure having completed positions in Colombia, Brazil, Spain, and
the UK.
Kim Stratton added, "I would like to thank René for his
contributions over the past year. He has significantly improved our
internal processes and has initiated a cost reduction process and
an acceleration of our annual reporting cycle. I want to
specifically commend him on securing a strong financial foundation
for CENTOGENE with the recently closed financing transactions. With
that milestone behind us, with a strong management team, and with a
significantly improved financial position, it is now time to
deliver on our long-term strategy. We wish René all the best in his
future endeavors, and we look forward to working with him through
the transition.”
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 600,000 patients representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media
Contact: CENTOGENE Ben
Legg Corporate Communications Press@centogene.com
Lennart Streibel Investor
Relations Investor.Relations@centogene.com Stern
IR Brendan Payne+1 (212) 698
8695Brendan.Payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024